We adopt the molecular hybridization technique to design new hybrids structurally containing benzimidazole core conjugated with different pharmacophores aiming to develop selective and more-effective anti-breast cancer agents via Pin1 inhibition (Chart 1). Here, PIN1 is linked to breast carcinoma.